Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients With Basal Cell Carcinoma

THOMSON REUTERS2024-08-14

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459312415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-14 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459312415","market":"us","top_or_hot":-1,"title":"Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients With Basal Cell Carcinoma","media":"THOMSON REUTERS","content":"<div>\n<p>Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUA3DLXZN:1\">Source Link</a>\n\n</div>\n","source":"reuters_en_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients With Basal Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients With Basal Cell Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-14 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUA3DLXZN:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUA3DLXZN:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VP..UK","symbol_name":"VP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUA3DLXZN:1","article_id":"2459312415","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459312415","pubTimestamp":1723635001,"columns":[],"sourceInfo":{"source_id":"reuters_en_live","name":"Thomson Reuters"},"weMediaInfo":null,"summary":"Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinic","collect":0,"end_time":0,"defaultTopTitle":"refinitiv.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VP..UK":"VP","VRCA":"Verrica Pharmaceuticals Inc.","BK5045":"贸易公司与经销商","BK4007":"制药"},"translate_title":"Verrica Pharmaceuticals宣布Vp-315（一种用于治疗基底细胞癌患者的基于溶瘤肽的研究性免疫疗法）2期临床研究第2部分的积极初步顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VP..UK":1,"VRCA":0.9},"content_text":"Verrica Pharmaceuticals Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients With Basal Cell Carcinoma","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459312415"}